Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meloxicam versus physiotherapy for temporomandibular disorder
IRCT20181113041642N1Phase 3Completed
- Sponsor
- Qom University of Medical Sciences
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of meloxicam in temporomandibular disorder (TMD) (2 arms), sponsored by Qom University of Medical Sciences. Primary endpoints: Masticatory muscle tenderness, Joint sounds and 3 more. Started Dec 2018; status: completed.
02
Drugs
meloxicam
03
Conditions
temporomandibular disorder (TMD)
Beyond the preview
Go deeper on IRCT20181113041642N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181113041642N1.